Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder

Pharmacogenomics Journal

Volumn 6, Issue 1, 2006, Pages 27-33

  Hong, C J ^a,b   Chen, T J ^c,d   Yu, Y W Y ^e   Tsai, S J ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d KAI SUAN PSYCHIATRIC HOSPITAL   (Taiwan)

^e Yu's Psychiatric Clinic   (Taiwan)

Author keywords

Fluoxetine; Pharmacogenetics; Polymorphism; Selective serotonin reuptake inhibitor; Serotonin 1A receptor

Indexed keywords

FLUOXETINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; PLACEBO; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIVIDUALIZATION; INTRON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOMES RESEARCH; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; TAIWAN; TANDEM REPEAT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TAIWAN; TREATMENT OUTCOME;

EID: 31044444151     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500340     Document Type: Article

References (41)

1. Neumeister A, Young T, Stastny J. Implications of genetic research on the role of the serotonin in depression: Emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology 2004; 174: 512-524.
2. Fava M. Management of nonresponse and intolerance: Switching strategies. J Clin Psychiatry 2000; 61(Suppl 2): 10-12.
3. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
4. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: A review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002; 5: 255-275.
5. Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003; 36(Suppl 3): S235-S243.
6. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-2624.
7. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5: 32-38.
8. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
9. Tsai SJ, Hong CJ. Pharmacogenetics of selective serotonin reuptake inhibitor response in major depression. Curr Pharmacogenom 2003; 1: 1-7.
10. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: A systematic review. Mol Psychiatry 2004; 9: 433-441.
11. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219.
12. Yoshid K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 383-386.
13. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P et al. Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression. Neurosci Lett 2001; 303: 119-122.
14. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
15. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
16. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000; 11: 1893-1897.
17. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR et al. Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6: 339-346.
18. Newman ME, Lerer B, Shapira B. 5-HT-1A receptor-mediated effects of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 1-19.
19. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215-235.
20. Suzuki Y, Sawamura K, Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J 2004; 4: 283-286.
21. Kobilka BK, Frielle T, Collins S, Yang-Feng T, Kobilka TS, Francke U et al. An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 1987; 329: 75-79.
22. Rothe C, Gutknecht L, Freitag C, Tauber R, Mossner R, Franke P et al. Association of a functional -1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol 2004; 7: 189-192.
23. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003; 23: 8788-8799.
24. Strobel A, Gutknecht L, Rothe C, Reif A, Mossner R, Zeng Y et al. Allelic variation in 5-HT 1A receptor expression is associated with anxiety- and depression-related personality traits. J Neural Transm 2003; 110: 1445-1453.
25. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: Preliminary findings. Int J Neuropsychopharmacol 2004; 7: 453-460.
26. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
27. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-1119.
28. Tsai SJ, Hong CJ, Cheng CY. Serotonin transporter genetic polymorphisms and harm avoidance in the Chinese. Psychiatr Genet 2002; 12: 165-168.
29. Hong CJ, Tsai SJ, Wang YC. Association between tryptophan hydroxylase gene polymorphism (A218C) and schizophrenic disorders. Schizophr Res 2001; 49: 59-63.
30. Lin CH, Tsai SJ, Yu YW, Song HL, Tu PC, Sim CB et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 1999; 10: 57-60.
31. Lin CN, Tsai SJ, Hong CJ. Association analysis of a functional G protein beta3 subunit gene polymorphism (C825T) in mood disorders. Neuropsychobiology 2001; 44: 118-121.
32. Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999; 60: 574-579.
33. Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003; 64: 921-926.
34. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53: 193-203.
35. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002; 106: 168-170.
36. Morishita S, Arita S. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol 2004; 19: 405-408.
37. Cidis Meltzer C, Drevets WC, Price JC, Mathis CA, Lopresti B, Greer PJ et al. Gender-specific aging effects on the serotonin 1A receptor. Brain Res 2001; 895: 9-17.
38. Parsey RV, Oquendo MA, Simpson NR, Ogden RT, Van Heertum R, Arango V et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res 2002; 954: 173-182.
39. Gobbi G, Murphy DL, Lesch K, Blier P. Modifications of the serotonergic system in mice lacking serotonin transporters: An in vivo electrophysiological study. J Pharmacol Exp Ther 2001; 296: 987-995.
40. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51: 723-732.
41. Murphy Jr GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835.